By Scientia Professor Gregory John Dore

Conference Papers

Grebely J; Matthews G; White PA; Renkin M; Flynn J; Ffrench R; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'Incidence and risk factors for HCV reinfection and superinfection in individuals treated for acute/early chronic HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A344

Matthews G; Grebely J; White PA; Renkin M; Marks PB; Ffrench R; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1844 - 1845, presented at Hepatology

Grebely J; Ngai T; Knight E; Duncan F; Raffa J; Genoway K; Showler G; Krajden M; Dore GJ; Conway B, 2008, 'Low rate of hepatitis C virus re-infection following sustained virological response among injection drug users having received treatment for HCV infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A338 - A338

Robotin M; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy MT, 2008, 'Modeling population-based chronic hepatitis B screening and treatment to prevent cirrhosis and liver cancer among high risk populations in Australia', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A358 - A359

White PA; Grebely J; Matthews G; Flynn J; Renkin M; Kaldor JM; Lloyd AR; Hellard M; Ffrench R; Dore GJ, 2008, 'Natural history of HCV reinfection and superinfection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A355 - A355

White PA; Grebely J; Flynn J; Matthews G; Renkin M; Yeung B; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Ffrench R; Dore GJ, 2008, 'NATURAL HISTORY OF HCV SUPERINFECTION AND REINFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1056 - 1057, presented at Hepatology

Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2008, 'PEGYLATED INTERFERON ALFA-2A (PEG-2A) PLUS RIBAVIRIN (RBV) FOR PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) ON OPIOID PHARMACOTHERAPY: VIROLOGICAL OUTCOMES, PSYCHOLOGICAL IMPACT AND SAFETY', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1310 - 1311, presented at Hepatology

Nguyen VT; Amin J; Law MG; Dore GJ, 2008, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A343 - A343

Jones T; Marks P; Connelly C; Warner S; Fragomeli V; Walker PJ; Ferguson CM; Dore GJ, 2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A241 - A241, presented at Journal of Gastroenterology and Hepatology

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Thio C; Bowden SJ; Ayres A; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'Tenofovir based HAART is associated with high rates of HBV DNA suppression and HBEAG seroconversion in thai HIV-HBV coinfected patients', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A336

Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology

Gidding H; Topp L; Middleton M; Dore G; Robinson K; Maher L; Kaldor J; Law M, 2008, 'The epidemiology of hepatitis C in Australia-a review of notifications, treatment uptake, and associated liver transplantations 1997-2006', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A379 - A379

Audsley J; Littlejohn M; Yuen L; Desmond C; Dore GJ; Ruxrungtham K; Locarnini S; Thio C; Lewin S; Revill P, 2008, 'Virological characteristics of a longitudinal HIV/HBV co-infected cohort prior to initiation of HBV-active HAART', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A336 - A337

Roberts S; Weltman M; Crawford D; Cheng W; Sievert W; McCaughan GW; Desmond PV; Yoshihara M; Miller JE; Depamphilis J; Marks P; Dore GJ, 2007, 'Rapid and early virological response rates are increased with 12 week 360 mu g/wk peginterferon alfa-2A (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: Efficacy and safety analysis of the induction phase of the CHARIOT study', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 257A - 258A, presented at 58th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, MA, Boston, 02 November 2007 - 06 November 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000249910400055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Roberts S; Cooksley G; Dore G; Robson R; Shaw D; Berns H; Brandt M; Fenner S; Hill G; Ipe D; Klumpp K; Mannino M; O'mara E; Najera I; Tu Y; Washington C, 2007, 'Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, DC, Washington, pp. A779 - A779, presented at Digestive Disease Weeking Meeting/ASGE Postgraduate Course Meeting, DC, Washington, 19 May 2007 - 24 May 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000245927606317&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Klumpp K; Smith D; Brandl M; Alfredson T; Sarma K; Smith M; Najera I; Jiang W-R; Le Pogam S; Leveque V; Ma H; Tu Y; Chan R; Chen C-W; Wu X; Birudaraj R; Swallow S; Martin JA; Cammack N; Berns H; Fettner S; Ipe D; Mannino M; O'Mara E; Washington C; Roberts S; Cooksley G; Dore G; Shaw D; Blue DR; Zahm F; Hill G, 2007, 'Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4'-azidocytidine) with enhanced oral bioavailability', in ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV, CA, Palm Spring, pp. A35 - A35, presented at 20th International Conference on Antiviral Research, CA, Palm Spring, 29 April 2007 - 03 May 2007, http://dx.doi.org/10.1016/j.antiviral.2007.01.029

McCaughan GW; Omata M; Amarapurkar D; Bowden S; Chow WC; Chutaputti A; Dore G; Gane E; Guan R; Hamid SS; Hardikar W; Hui CK; Jafri W; Jia JD; Lai MY; Wei L; Leung N; Piratvisuth T; Sarin S; Sollano J; Tateishi R, 2007, 'Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection', in Journal of Gastroenterology and Hepatology Australia, pp. 615 - 633, http://dx.doi.org/10.1111/j.1440-1746.2007.04883.x

Campbell S; Norris S; Mernagh P; Batey R; Dore GJ, 2006, 'Economic modelling to determine the cost-effectiveness of treatment of patients with histologically mild chronic hepatitis C with pegylated interferon alpha-2b plus ribavirin', in VALUE IN HEALTH, ELSEVIER SCIENCE INC, pp. A307 - A307, http://dx.doi.org/10.1016/S1098-3015(10)63528-0

Nguyen VT; Razali K; Amin J; Law MG; Dore GJ, 2006, 'Estimates of Hepatitis B-Realted Liver Cancer Among Vietnam Born Population in Australia', in 18th Annual ASHM Conference, Melbourne, pp. 152 - 153, presented at 18th Annual ASHM Conference, Melbourne, 11 October 2006 - 14 October 2006

Nguyen VT, 2006, 'Highly endemic Hepatitis B infection in Rural Vietnam', in Shanghai - Hong Kong International Liver Congress 2006, Shanghai, presented at Shanghai - Hong Kong International Liver Congress 2006, Shanghai, 25 March 2006 - 28 March 2006

Nguyen VT; McLaws M; Dore GJ, 2006, 'Highly endemic hepatitis B infection in rural Vietnam', in Hepatitis 5th Australian Conference, Sydney, pp. 20 - 22, presented at Hepatitis 5th Australian Conference, Sydney, 20 February 2006 - 22 February 2006

Ffrench RA; Flynn J; Goy K; Hosseiny P; Pan Y; Rawlinson WD; White PA; Nguyen O; Hellard M; Kaldor JM; Dore GJ; Lloyd AR, 2006, 'Comprehensive analysis of IFN-gamma and IL-2 production by T cells in acute and chronic HCV infection', in Journal of Clinical Virology, Elsevier Science BV, Amsterdam, Netherlands, pp. S123 - S123, presented at Journal of Clinical Virology, Melbourne

Nguyen VT; McLaws M; Dore GJ, 2006, 'Highly endemic hepatitis B infection in rural Vietnam', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia

Hellard M; Dore G; Haber P; Marks P; Matthews G; Yeung B; Nguyen O; Pan Y; Ffrench R; McCaughan G; Van Beek I; White P; Dolan K; Rawlinson W; Lloyd A; Kaldor J, 2006, 'P.250 Australian trial in acute hepatitis C: preliminary findings', in Journal of Clinical Virology, Elsevier, pp. s139, http://dx.doi.org/10.1016/s1386-6532(06)80430-0

Amin J; Law MG; Bartlett M; Kaldor JM; Dore GJ, 2005, 'Causes of death in people with hepatitis B or C infection: A population based cohort study', in HEPATOLOGY, WILEY-BLACKWELL, CA, San Francisco, pp. 214A - 214A, presented at 56th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, CA, San Francisco, 11 November 2005 - 15 November 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000232480300046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hardikar W; Polis S; Kesson A; Mews C; Jones C; Elliott E; Dore G; Kaldor J, 2004, 'National surveillance of hepatitis C virus infection in Australian children.', in HEPATOLOGY, JOHN WILEY & SONS INC, MA, Boston, pp. 415A - 415A, presented at 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 29 October 2004 - 02 November 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000224102100578&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Freeman AJ; Law MG; Kaldor JM; Dore GJ, 2002, 'Hepatitis C: The Australian experience.', in HEPATOLOGY, W B SAUNDERS CO, MASSACHUSETTS, BOSTON, pp. 554A - 554A, presented at 53rd Annual Meeting of the Association-for-the-Study-of-Liver-Diseases (AASLD), MASSACHUSETTS, BOSTON, 01 November 2002 - 05 November 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178301701545&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wettstein AR; Maddocks S; Dore G; Edwards P, 1999, 'Association of cryptosporidiosis to HIV-related cholangiopathy and the role of protease inhibitors', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. A39 - A39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000079778400165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wettstein A; Dore G; Murphy C; Hing M; Edwards P, 1997, 'HIV-related cholangiopathy in Australia', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, pp. A1117 - A1117, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WV41904452&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters

Price O; Dietze P; Maher L; Dore G; Trent M; Sutherland R; Karlsson A; Uporova J; Chandrasena K; Gibbs D; Swanton R; Salom C; Lenton S; Bruno R; Degenhardt L; Farrell M; Peacock A, 2021, 'Barriers and facilitators to COVID-19 vaccination among Australians who inject drugs: how can we maximise uptake?', Sydney, presented at NDARC Annual Research Symposium, Sydney, 20 October 2021

Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham E; Estes C; Razavi H; Gray RT, 2018, 'Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake', presented at International Liver Congress (European Association for the Study of the Liver (EASL 2018)), 11 April 2018 - 15 April 2018

Cunningham EB; Hajarizadeh B; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Bretana NA; Dolan K; Lloyd AR; Grebely J, 2018, 'Ongoing incident hepatitic c virus infection among people with a history of injecting drug use in an Australian prison setting', Vol. 1, pp. 278 - 280, http://dx.doi.org/10.1093/JCAG/GWY008.162

Conference Presentations

Price O; Dietze P; Maher L; Dore G; Trent M; Sutherland R; Karlsson A; Uporova J; Chandrasena K; Gibbs D; Swanton R; Salom C; Lenton S; Bruno R; Degenhardt L; Farrell M; Peacock A, 2021, 'COVID-19 vaccine hesitancy among Australians who use drugs', presented at APSAD conference, Virtual, 07 November 2021

Lafferty L; Rance J; Grebely J; Dore G; Lloyd A; Treloar C, 2021, 'Perceptions and concerns of hepatitis c reinfection in the prison setting', presented at Justice Health Conference, Public Health Association Australia, Virtual (Australia), 03 November 2021 - 04 November 2021

Lafferty L; Rance J; Grebely J; Dore G; Lloyd A; Treloar C, 2021, 'Correctional Officers and Health Staff Perspectives Of Hepatitis C Treatment As Prevention Scale Up Within The Prison Setting', presented at International Conference on Health and Hepatitis in Substance Users (INHSU), Virtual (International), 13 October 2021 - 15 October 2021

Lafferty L; Rance J; Dore G; Lloyd A; Treloar C, 2021, 'Scaling Up Hepatitis C Treatment within the Prison Setting: The Role of Social Capital', presented at Academic and Health Policy Conference on Correctional Health (ACCJH), Virtual (USA), 08 April 2021 - 10 April 2021

Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Homie R; Gray RT, 2018, 'Ongoing Burden of Advanced Liver Disease Complications Despite Rapid HCV Treatment Scale-Up', presented at Australasian Viral Hepatitis Conference, 13 August 2018 - 15 August 2018

Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'Australia Could Meet the WHO HCV Elimination Targets If the Current Rollout of DAA Treatment Is Continued', presented at Australasian Viral Hepatitis Conference (AVHC), 10 August 2017 - 11 August 2017

Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression', presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30286-6

Byrne M; Hajarizadeh B; Dore GJ; Treloar C; Marks P; Milat A; Bowman J; McGrath C; Bath N; Calder I; Lagios K; Grebely J; Lloyd A, 2017, 'FRI-193 A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit', http://dx.doi.org/10.1016/s0168-8278(17)31387-9

Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'THU-232 The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', http://dx.doi.org/10.1016/s0168-8278(17)30899-1

Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G; Law M, 2016, 'Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014', presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016

Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016

Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G; Swan T; Backmund M; Marks P; Grebely J; Dore GJ; Applegate TL, 2016, 'FRI-195 Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool, including for Post-Treatment Relapse', http://dx.doi.org/10.1016/s0168-8278(16)01163-6

Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J; Marks P; Quiene S; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Bourgeois S; Thurnheer C; Dore GJ; Group OBOTACTIVATES, 2015, 'P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study', presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, AUSTRIA, Vienna, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/s0168-8278(15)31050-3

Conference Abstracts

Matthews N; Vogt H; Richmond J; Armstrong P; Combo T; Hosking K; Armstrong A; Quagliotto C; Dally G; Marukutira T; Wallace J; Dore G; Treloar C; Davies J; Doyle J; Pedrana A; Hellard M; Stoove M, 2026, 'From lived experience to action: Turning notifications data into hepatitis C Care', in Australian and New Zealand Journal of Public Health, Elsevier, Vol. 50, pp. 100557, http://dx.doi.org/10.1016/j.anzjph.2026.100557

Price O; Dietze PM; Maher L; Dore GJ; Crawford S; Sutherland R; Salom C; Bruno R; Lenton S; Degenhardt L; Peacock A, 2022, 'COVID-19 pandemic experiences of people in Australia who inject drugs: Analysis of illicit drug reporting system interview data 2020-2022', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S115 - S115

Bin Usman Shah SH; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Innes H; Dore G, 2022, 'FRI339 Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets', in Journal of Hepatology, Elsevier, Vol. 77, pp. s560, http://dx.doi.org/10.1016/s0168-8278(22)01443-x

Lockart I; Yeo MGH; Hajarizadeh B; Dore G; Danta M, 2022, 'FRI343 Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis', in Journal of Hepatology, Elsevier, Vol. 77, pp. s561 - s562, http://dx.doi.org/10.1016/s0168-8278(22)01445-3

Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'FRI349 Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier, Vol. 77, pp. s565, http://dx.doi.org/10.1016/s0168-8278(22)01451-9

Back to profile page